

Fernando Magro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4836785/publications.pdf>

Version: 2024-02-01

279
papers

13,620
citations

46918

47
h-index

25716

108
g-index

285
all docs

285
docs citations

285
times ranked

12107
citing authors

#	ARTICLE	IF	CITATIONS
1	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	0.6	1,324
2	Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 443-468.	0.6	804
3	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
4	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 965-990.	0.6	715
5	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	0.6	541
6	European consensus on the histopathology of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 827-851.	0.6	521
7	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
8	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
9	The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 107-124.	0.6	369
10	Immune-Related Systemic Manifestations of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 29-34.	1.1	334
11	East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. <i>Gut</i> , 2014, 63, 588-597.	6.1	321
12	Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 477-483.	0.6	310
13	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 4-25.	0.6	285
14	European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 873-885.	0.6	185
15	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	0.6	185
16	ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 879-913.	0.6	177
17	Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2002, 47, 216-224.	1.1	175
18	Long-Term Safety of In Utero Exposure to Anti-TNF \pm Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 396-403.	0.2	134

#	ARTICLE	IF	CITATIONS
19	Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III). <i>Journal of Crohn's and Colitis</i> , 2014, 8, 31-44.	0.6	130
20	European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. <i>United European Gastroenterology Journal</i> , 2021, 9, 13-37.	1.6	122
21	Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 573-583.	0.9	116
22	Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2098-2110.	0.9	106
23	Oxidative Stress and DNA Damage. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	100
24	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 198-208.	0.6	100
25	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1503-1511.	0.6	100
26	Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies. <i>BioDrugs</i> , 2010, 24, 3-14.	2.2	84
27	The histopathological approach to inflammatory bowel disease: a practice guide. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 511-27.	1.4	83
28	Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels. <i>Gut</i> , 2019, 68, 594-603.	6.1	83
29	Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S798-S806.	0.6	83
30	Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1506-1515.	0.6	82
31	Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 607-616.	0.6	81
32	Is it Possible to Change Phenotype Progression in Crohn's Disease in the Era of Immunomodulators? Predictive Factors of Phenotype Progression. <i>American Journal of Gastroenterology</i> , 2014, 109, 1026-1036.	0.2	81
33	Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. <i>World Journal of Gastroenterology</i> , 2015, 21, 7584.	1.4	81
34	Venous thrombosis and prothrombotic factors in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 4857.	1.4	79
35	Metabolic Inflammation in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 453-467.	0.9	77
36	High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 129-136.	0.6	76

#	ARTICLE	IF	CITATIONS
37	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 454-464.	3.7	76
38	Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 36-46.	0.9	71
39	Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. <i>Pharmacological Research</i> , 2020, 159, 104947.	3.1	71
40	Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1104-1112.	0.6	68
41	The NAD ⁺ -dependent deacetylase SIRT2 attenuates oxidative stress and mitochondrial dysfunction and improves insulin sensitivity in hepatocytes. <i>Human Molecular Genetics</i> , 2017, 26, 4105-4117.	1.4	67
42	Results of the 4th Scientific Workshop of the ECCO (Group II): Markers of intestinal fibrosis in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1166-1178.	0.6	65
43	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019, 37, 266-283.	0.8	63
44	Nocardia infections among immunomodulated inflammatory bowel disease patients: A review. <i>World Journal of Gastroenterology</i> , 2015, 21, 6491.	1.4	60
45	Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease – An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1030-1042.	0.6	59
46	Tuberculosis in anti-TNF- α treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e486-e492.	0.6	56
47	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	8.2	56
48	Anaemia management in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1456-1463.	0.8	52
49	Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 684-692.	1.9	51
50	Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure. <i>American Journal of Gastroenterology</i> , 2020, 115, 179-189.	0.2	50
51	Clinical Trials in Ulcerative Colitis: A Historical Perspective. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 580-588.	0.6	48
52	Listeria infection in patients on anti-TNF treatment: Report of two cases and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 175-182.	0.6	47
53	Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 121-131.	0.9	47
54	DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1316-1323.	0.6	46

#	ARTICLE	IF	CITATIONS
55	Soluble Selectins, sICAM, sVCAM, and Angiogenic Proteins in Different Activity Groups of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1265-1274.	1.1	44
56	Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 723-725.	0.9	44
57	Inflammatory Bowel Disease – Non-biological treatment. <i>Pharmacological Research</i> , 2020, 160, 105075.	3.1	44
58	Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. <i>Acta Physiologica Scandinavica</i> , 2004, 180, 379-386.	2.3	43
59	Anti-TNF-Alpha Induced Psoriasiform Eruptions with Severe Scalp Involvement and Alopecia: Report of Five Cases and Review of the Literature. <i>Dermatology</i> , 2012, 225, 163-167.	0.9	43
60	Epstein-Barr Virus in Inflammatory Bowel Disease – Correlation with Different Therapeutic Regimens. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1710-1716.	0.9	43
61	High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1157-1163.	0.8	42
62	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1181-1187.	1.9	42
63	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	3.7	42
64	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	2.4	39
65	Looking into Enteric Virome in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1278-1284.	0.9	39
66	Inflammatory Bowel Disease: A Patient's and Caregiver's Perspective. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2671-2679.	1.1	38
67	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 747-753.	0.6	38
68	Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1407-1416.	0.6	38
69	Dopamine D2 Receptor Polymorphisms in Inflammatory Bowel Disease and the Refractory Response to Treatment. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2039-2044.	1.1	37
70	Phenotype-Genotype Profiles in Crohn's Disease Predicted by Genetic Markers in Autophagy-Related Genes (GOIA Study II). <i>Inflammatory Bowel Diseases</i> , 2013, 19, 230-239.	0.9	37
71	The daily impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2020, 8, 520-527.	1.6	37
72	Macrophages from IBD patients exhibit defective tumour necrosis factor- α secretion but otherwise normal or augmented pro-inflammatory responses to infection. <i>Immunobiology</i> , 2011, 216, 961-970.	0.8	36

#	ARTICLE	IF	CITATIONS
73	Imaging techniques in IBD and their role in follow-up and surveillance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 722-736.	8.2	36
74	Prevalence of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> and <i>Escherichia coli</i> in blood samples from patients with inflammatory bowel disease. <i>Medical Microbiology and Immunology</i> , 2015, 204, 681-692.	2.6	36
75	Clinical prognostic factors for disabling Crohn's disease: A systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2013, 19, 3866.	1.4	35
76	Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1054-1069.	2.4	34
77	Role of epithelial ion transports in inflammatory bowel disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G460-G476.	1.6	33
78	Correlation Between Calprotectin and Modified Rutgeerts Score. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2173-2181.	0.9	32
79	A Systematic Review on Infliximab and Adalimumab Drug Monitoring. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2289-2301.	0.9	31
80	Gut bacterial microbiome composition and statin intake—A systematic review. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00601.	1.1	31
81	Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization. <i>Gastroenterology</i> , 2020, 159, 14-19.e3.	0.6	31
82	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	1.6	31
83	Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 342-349.	0.6	30
84	Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1574-1581.	1.4	30
85	Ulcerative colitis in northern Portugal and Galicia in Spain. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1227-1238.	0.9	27
86	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1605-1613.	0.9	27
87	Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1297-1303.	0.8	27
88	Endoscopic balloon dilation of Crohn's disease strictures—safety, efficacy and clinical impact. <i>World Journal of Gastroenterology</i> , 2017, 23, 7397-7406.	1.4	27
89	Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 499-510.	0.9	26
90	Prevalence, risk factors and global impact of musculoskeletal injuries among endoscopists: a nationwide European study. <i>Endoscopy International Open</i> , 2020, 08, E470-E480.	0.9	26

#	ARTICLE	IF	CITATIONS
91	Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 1087-1089.	0.9	25
92	Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 169-175.	0.6	25
93	Infliximab therapy increases the frequency of circulating CD16+monocytes and modifies macrophage cytokine response to bacterial infection. <i>Clinical and Experimental Immunology</i> , 2014, 177, 703-711.	1.1	24
94	Metastatic cutaneous Crohn's disease of the face. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 954-956.	0.8	23
95	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort: An ECCO-EpiCom Study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1213-1222.	0.6	23
96	Crohn's disease in a southern European country: Montreal classification and clinical activity. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1343-1350.	0.9	22
97	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in Ulcerative Colitis: the ACERTIVE study. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jiw170.	0.6	22
98	Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. <i>Digestive and Liver Disease</i> , 2017, 49, 1289-1297.	0.4	22
99	Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 835-844.	0.6	22
100	Signaling of short- and long-term regulation of intestinal epithelial type 1 Na ⁺ /H ⁺ exchanger by interferon- β . <i>British Journal of Pharmacology</i> , 2005, 145, 93-103.	2.7	21
101	Case Series: Ulcerative Colitis, Multiple Sclerosis, and Interferon-Beta 1a. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2001-2003.	0.9	21
102	Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 811-818.	0.6	21
103	A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1381-1392.	0.6	21
104	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. <i>Digestive and Liver Disease</i> , 2020, 52, 138-142.	0.4	21
105	The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin. <i>United European Gastroenterology Journal</i> , 2020, 8, 1208-1216.	1.6	21
106	Sexual Quality of Life in Inflammatory Bowel Disease: A Multicenter, National-Level Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 746-755.	0.9	21
107	ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 876-883.	0.6	21
108	Oral squamous cell carcinoma in a Crohn's disease patient taking azathioprine: Case report and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 792-795.	0.6	20

#	ARTICLE	IF	CITATIONS
109	Development and Validation of Risk Matrices for Crohn's Disease Outcomes in Patients Who Underwent Early Therapeutic Interventions. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jiw171.	0.6	20
110	Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481876907.	1.4	20
111	Antigenic response to <sc>CT</sc>P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 507-522.	1.9	20
112	Genetic Variants of the MGAT5 Gene Are Functionally Implicated in the Modulation of T Cells Glycosylation and Plasma IgG Glycome Composition in Ulcerative Colitis. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00166.	1.3	20
113	C-reactive protein in Crohn's disease: how informative is it?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 393-408.	1.4	19
114	Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 996-1003.	1.4	19
115	Anaemia in Patients with Inflammatory Bowel Disease - A Nationwide Cross-Sectional Study. <i>Digestion</i> , 2016, 93, 214-220.	1.2	18
116	Serial Tuberculosis Screening in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1223-1229.	0.6	18
117	New cross-sectional imaging in IBD. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 194-207.	1.0	18
118	Comparison of the Nancy Index With Continuous Geboes Score: Histological Remission and Response in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1021-1025.	0.6	18
119	COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. <i>United European Gastroenterology Journal</i> , 2021, 9, 750-765.	1.6	18
120	Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision. <i>Frontiers in Medicine</i> , 2020, 7, 590527.	1.2	18
121	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
122	Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling Outcomes. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 289-297.	0.9	17
123	Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1232-1244.	0.6	17
124	Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes—Bayesian Network Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 401-409.	0.6	17
125	The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up— an Epi-IBD study. <i>United European Gastroenterology Journal</i> , 2020, 8, 949-960.	1.6	17
126	Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2017, 12, e0169102.	1.1	17

#	ARTICLE	IF	CITATIONS
127	Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 661-671.	1.4	16
128	Clinical performance of an infliximab rapid quantification assay. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 651-660.	1.4	16
129	Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1066-1073.	0.6	16
130	Dose optimisation for Loss of Response to Vedolizumab's Pharmacokinetics and Immune Mechanisms. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1707-1719.	0.6	16
131	Intestinal 5-Hydroxytryptamine and Mast Cell Infiltration in Rat Experimental Colitis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 495-501.	1.1	15
132	Ulcerative colitis in a Southern European country: A national perspective. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 822-829.	0.9	15
133	Disseminated cutaneous herpes simplex infection in a patient with Crohn's disease under azathioprine and steroids: First case report and literature review. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 326-330.	0.6	15
134	Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 781-794.	1.4	15
135	Cutaneous Morbidity Among Inflammatory Bowel Disease Patients: A Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 442-451.	0.6	15
136	Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1387-1393.	0.6	15
137	Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years. <i>Digestive and Liver Disease</i> , 2019, 51, 952-960.	0.4	15
138	Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 2216.	1.0	15
139	Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review. <i>American Journal of Physiology - Cell Physiology</i> , 2021, 320, C520-C546.	2.1	15
140	Intestinal Na ⁺ -K ⁺ -ATPase activity and molecular events downstream of interferon- β receptor stimulation. <i>British Journal of Pharmacology</i> , 2004, 142, 1281-1292.	2.7	14
141	Interferon- β -induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells. <i>Biochemical Pharmacology</i> , 2005, 70, 1312-1319.	2.0	14
142	Crohn's disease outcome in patients under azathioprine: A tertiary referral center experience. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 617-625.	0.6	14
143	The risk of disabling, surgery and reoperation in Crohn's disease – A decision tree-based approach to prognosis. <i>PLoS ONE</i> , 2017, 12, e0172165.	1.1	14
144	Advanced imaging techniques for small bowel Crohn's disease: what does the future hold?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1875718.	1.4	14

#	ARTICLE	IF	CITATIONS
145	Interaction between the Renin-Angiotensin System and Enteric Neurotransmission Contributes to Colonic Dysmotility in the TNBS-Induced Model of Colitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4836.	1.8	14
146	Ionizing radiation exposure is still increasing in Crohn's disease: Who should be blamed?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1214-1225.	0.6	13
147	Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1707-1719.	0.9	13
148	What forecasting the prevalence of inflammatory bowel disease may tell us about its evolution on a national scale. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986004.	1.4	12
149	Accuracy of the new rapid test for monitoring adalimumab levels. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481982823.	1.4	12
150	Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1787-1795.	0.9	12
151	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2567-2576.e9.	2.4	12
152	Is tofacitinib a game-changing drug for ulcerative colitis?. <i>United European Gastroenterology Journal</i> , 2020, 8, 755-763.	1.6	12
153	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	2.5	12
154	Challenges and Opportunities in IBD Clinical Trial Design. <i>Gastroenterology</i> , 2021, 161, 400-404.	0.6	11
155	Regional intestinal adaptations in Na ⁺ ,K ⁺ -ATPase in experimental colitis and the contrasting effects of interferon-gamma. <i>Acta Physiologica Scandinavica</i> , 2005, 183, 191-199.	2.3	10
156	Liver abscess of the caudate lobe due to <i>Staphylococcus aureus</i> in an ulcerative colitis patient: First case report. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 360-363.	0.6	10
157	The who-when-why triangle of complementary and alternative medicine use among Portuguese IBD patients. <i>Digestive and Liver Disease</i> , 2017, 49, 388-396.	0.4	10
158	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	0.6	10
159	Methylation patterns in dysplasia in inflammatory bowel disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 646-655.	0.6	10
160	Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. <i>Advances in Therapy</i> , 2022, 39, 2342-2364.	1.3	10
161	Gingival Hyperplasia as a First Manifestation of Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1946-1949.	1.1	9
162	The effect of PRR ligands on the membrane potential of intestinal epithelial cells. <i>Pharmacological Reports</i> , 2017, 69, 978-984.	1.5	9

#	ARTICLE	IF	CITATIONS
163	Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096579.	1.4	9
164	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
165	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000853.	1.1	9
166	Infliximab dose intensification by shortening infusion intervals. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 432-434.	0.9	8
167	Severe gram positive bacterial infection in an ulcerative colitis patient treated with Infliximab. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 110-113.	0.6	8
168	Short- and Long-Term Regulation of Intestinal Na ⁺ /H ⁺ Exchange Activity Associated with TLR2 Receptor Activation Is Independent of Nuclear Factor- κ B Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 453-464.	1.3	8
169	Reintroduction of Anti-TNF \pm Therapy After (or even During) Anti-TNF \pm -associated Tuberculosis in Immune-mediated Diseases: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 120-121.	0.6	8
170	Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation. <i>EBioMedicine</i> , 2017, 21, 123-130.	2.7	8
171	The performance of Remicade [®] -optimized quantification assays in the assessment of Flixabi [®] levels. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879695.	1.4	8
172	Utility of stent double palliation for esophageal cancer with airway involvement: the extremis of care. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	8
173	Aminosalicylates and COVID-19: Facts or Coincidences?. <i>Gastroenterology</i> , 2021, 160, 1884-1885.	0.6	8
174	Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 551-566.	0.6	8
175	Ileal Crohn's Disease Exhibits Similar Transmural Fibrosis Irrespective of Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00330.	1.3	8
176	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
177	Short-term effect on intestinal epithelial Na ⁺ /H ⁺ exchanger by Gi \pm 1,2-coupled 5-HT _{1A} and Gq/11-coupled 5-HT ₂ receptors. <i>Life Sciences</i> , 2007, 81, 560-569.	2.0	7
178	How to Manage Pouchitis in Ulcerative Colitis?. <i>Current Drug Targets</i> , 2011, 12, 1454-1461.	1.0	7
179	Immunisations in Crohn's disease: Who? Why? What? When?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 485-496.	1.0	7
180	Increased viability but decreased culturability of <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> in macrophages from inflammatory bowel disease patients under Infliximab treatment. <i>Medical Microbiology and Immunology</i> , 2015, 204, 647-656.	2.6	7

#	ARTICLE	IF	CITATIONS
181	Amine neurotransmitters, inflammation and epithelial sodium transport. <i>Experimental Physiology</i> , 2016, 101, 459-464.	0.9	7
182	Transmural healing in Crohn's disease: Beyond mural findings. <i>Digestive and Liver Disease</i> , 2018, 50, 103-104.	0.4	7
183	Short Inflammatory Bowel Disease Questionnaire: translation and validation to the Portuguese language. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 59.	1.0	7
184	Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00320.	1.3	7
185	Fecal marker levels as predictors of need for endoscopic balloon dilation in Crohn's disease patients with anastomotic strictures. <i>World Journal of Gastroenterology</i> , 2017, 23, 6482-6490.	1.4	7
186	Incidence Trends of Inflammatory Bowel Disease in a Southern European Country: A Mirror of the Western World?. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00481.	1.3	7
187	Unusual Presentation of Tuberculosis After Infliximab Therapy. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 82-84.	0.9	6
188	Reactive Hepatitis in a Patient with Crohn's Disease Successfully Treated With Infliximab: Does Tumor Necrosis Factor Alpha Play a Role in Reactive Hepatitis?. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 88-90.	0.9	6
189	Systematic review on drug and diet-induced endoscopic remission in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 491-503.	0.8	6
190	Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 301-311.	0.6	6
191	Short- and long-term regulation of intestinal Na ⁺ /H ⁺ exchange by Toll-like receptors TLR4 and TLR5. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G703-G715.	1.6	6
192	Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 390-391.	3.7	6
193	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, , 1-8.	0.6	6
194	Mimicry between intestinal Behçet's disease and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 714-715.	0.6	5
195	Assessing overall patient satisfaction in inflammatory bowel disease using structural equation modeling. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 941-950.	0.8	5
196	The timing of early therapeutic strategies has a significant impact on Crohn's disease prognosis. <i>Digestive and Liver Disease</i> , 2018, 50, 462-468.	0.4	5
197	Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 743-756.	0.6	5
198	Do Neutrophils Contribute to Development of Crohn's Disease and Ulcerative Colitis?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2430-2431.	2.4	5

#	ARTICLE	IF	CITATIONS
199	Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00309.	1.3	5
200	The Process of Developing a Disease Activity Index in Microscopic Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 452-459.	0.6	5
201	Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 51-61.	0.9	5
202	Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 54-72.	1.6	5
203	Earlier need of infliximab intensification in Ulcerative Colitis than in Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1331-1332.	0.6	4
204	Varicella Complicated by Severe Pneumonia and Shock in an Immunosuppressed Crohn's Disease Patient Under Azathioprine and Anti-Tumour Necrosis Factor Alpha: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1176-1178.	0.6	4
205	The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients. <i>Digestive and Liver Disease</i> , 2016, 48, 1438-1443.	0.4	4
206	Refractory monogenic Crohn's disease due to X-linked inhibitor of apoptosis deficiency. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1235-1236.	1.0	4
207	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481986914.	1.4	4
208	Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?. <i>Current Medicinal Chemistry</i> , 2019, 26, 248-258.	1.2	4
209	A Narrative Review on Anti-Tumor Necrosis Factor ± Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact. <i>Acta Medica Portuguesa</i> , 2019, 32, 305-312.	0.2	4
210	The Impact of SARS-CoV-2 on Inflammatory Bowel Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2020, 27, 227-229.	0.3	4
211	DOP13 Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S049-S052.	0.6	4
212	Epithelial Neutrophilic Infiltrate: The Rising Star in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1509-e1510.	2.4	4
213	The Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1153-1165.	0.9	4
214	Chronic Granulomatous Disease Mimicking Colonic Crohn's Disease Successfully Treated with Infliximab. <i>ACG Case Reports Journal</i> , 2017, 4, e46.	0.2	4
215	The Magnitude of Crohn's Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. <i>Inflammatory Bowel Diseases</i> , 2022, , .	0.9	4
216	Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2059-2073.e7.	2.4	4

#	ARTICLE	IF	CITATIONS
217	Listeria monocytogenes bacteremia and CMV colitis in a patient with Ulcerative Colitis. Journal of Crohn's and Colitis, 2014, 8, 254-255.	0.6	3
218	Anti-TNF treatment failure: drug levels, immunogenicity, or both?. The Lancet Gastroenterology and Hepatology, 2019, 4, 326-327.	3.7	3
219	Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence. Clinical and Translational Gastroenterology, 2020, 11, e00227.	1.3	3
220	Heterogeneity of endoscopic full-thickness resection scars. Gastrointestinal Endoscopy, 2020, 92, 433-434.	0.5	3
221	Inflammatory Bowel Disease in Migrant Populations: Should we Look Even Further Back?. Current Drug Targets, 2021, 22, 1706-1715.	1.0	3
222	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. Digestive and Liver Disease, 2021, 53, 1571-1579.	0.4	3
223	Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed allergic tumor of the peritoneum. Scandinavian Journal of Gastroenterology, 2005, 40, 1251-1254.	0.6	2
224	Foreword. BioDrugs, 2010, 24, 1-2.	2.2	2
225	Dysplasia surveillance in an ulcerative colitis patient: Successful detection with Narrow band imaging and magnification. Journal of Crohn's and Colitis, 2011, 5, 54-56.	0.6	2
226	Response to Targownik. American Journal of Gastroenterology, 2015, 110, 349-351.	0.2	2
227	Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?. Scandinavian Journal of Gastroenterology, 2016, 51, 679-683.	0.6	2
228	Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures. Alimentary Pharmacology and Therapeutics, 2018, 47, 1033-1034.	1.9	2
229	Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis. United European Gastroenterology Journal, 2019, 7, 1153-1155.	1.6	2
230	Health-Related Quality of Life in Patients with Moderate to Severe Ulcerative Colitis: Surgical Intervention versus Immunomodulatory Therapy. Digestion, 2020, 101, 631-637.	1.2	2
231	Gastroenterological features of COVID-19 and the role of the United European Gastroenterology Journal. United European Gastroenterology Journal, 2020, 8, 505-506.	1.6	2
232	Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab. BioDrugs, 2021, 35, 35-45.	2.2	2
233	2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norvegicus: a categorization proposal. Experimental Animals, 2021, 70, 245-256.	0.7	2
234	Concurrent Lip Chancre and Maculopapular Syphilides in a Patient under Anti-TNF Therapy. Skinmed, 2019, 17, 343-345.	0.0	2

#	ARTICLE	IF	CITATIONS
235	Response to Irwin et al.. American Journal of Gastroenterology, 2015, 110, 933-935.	0.2	1
236	Preliminary Study for a Bayesian Network Prognostic Model for Crohn's Disease. , 2015, , .		1
237	Stool Isolation of Nocardia nova in Two Immunomodulated Patients With Inflammatory Bowel Diseases. Journal of Clinical Gastroenterology, 2016, 50, 92.	1.1	1
238	Anti-TNF therapy and radiation exposure in Crohn's disease: chicken or egg?. Scandinavian Journal of Gastroenterology, 2016, 51, 511-512.	0.6	1
239	Fibrosis in Ulcerative Colitis. , 2018, , 147-157.		1
240	Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach. Digestive Diseases, 2018, 36, 346-353.	0.8	1
241	Young GI angle: Tips and tricks for an academic career. United European Gastroenterology Journal, 2018, 6, 952-954.	1.6	1
242	OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. Journal of Crohn's and Colitis, 2019, 13, S009-S010.	0.6	1
243	P202 Quantum blue anti-infliximab: development and evaluation of a point of care rapid test for measuring anti-infliximab antibodies in human serum. Journal of Crohn's and Colitis, 2019, 13, S194-S195.	0.6	1
244	Delayed Intramural Duodenal Hematoma After a Simple Diagnostic Endoscopic Ultrasonography Fine-Needle Aspiration Procedure. ACG Case Reports Journal, 2019, 6, e00279.	0.2	1
245	Is Faecal Calprotectin Important in Detecting Silent Gut Inflammation in Seronegative Arthropathies?. Journal of Crohn's and Colitis, 2020, 14, 886-887.	0.6	1
246	Rectal Perforation by a Balloon Spacer: A Rare Cause of Rectal Perforation Addressed Endoscopically. GE Portuguese Journal of Gastroenterology, 2021, 28, 416-419.	0.3	1
247	Gynecological history up to diagnosis and pregnancy outcomes in diagnosed Wilson's disease under therapy i; 1/2 a bicentric matched control cohort study. Revista Espanola De Enfermedades Digestivas, 2020, , .	0.1	1
248	DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. Journal of Crohn's and Colitis, 2022, 16, i132-i134.	0.6	1
249	DOP56 Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, i103-i105.	0.6	1
250	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 2023, 21, 161-167.	1.0	1
251	Composite outcomes in observational studies of Crohn's disease: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210927.	1.4	1
252	UEG journal: The voice of European Gastroenterology. United European Gastroenterology Journal, 2022, 10, 523-524.	1.6	1

#	ARTICLE	IF	CITATIONS
253	PTU-072...Discontinuation of Infliximab in Patients with Ulcerative Colitis is Associated with Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Gut</i> , 2016, 65, A88-A89.	6.1	0
254	Disabling and Reoperation in Patients with Crohn's Disease Subject to Early Surgery or Immunosuppression: A Bayesian Network Prognostic Model. , 2016, , .		0
255	“A book should not be judged by its cover” two cases of intestinal adenocarcinoma as the first manifestation of Crohn’s disease. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1061-1062.	1.0	0
256	P812 Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort—the Epi-IBD cohort. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S523-S524.	0.6	0
257	P014 Proinflammatory cytokines and bile salts inhibit the cellular uptake of butyrate by Caco-2 cells. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S098-S100.	0.6	0
258	Editorial: antigenic response to CT ¹³ and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 575-576.	1.9	0
259	FRI-253-Changing epidemiology of hepatitis C: A Hospital-level study. <i>Journal of Hepatology</i> , 2019, 70, e505-e506.	1.8	0
260	P153 Quantum blue anti-adalimumab: development and evaluation of a point of care rapid test for measuring anti-adalimumab antibodies in human serum. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S165-S166.	0.6	0
261	P780 Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010–2011 cohorts. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S510-S511.	0.6	0
262	P740 Sexual quality of life in inflammatory bowel disease: a multi-centre, national-level study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S491-S491.	0.6	0
263	P113 Accuracy of a new rapid test assay for monitoring adalimumab levels. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S144-S144.	0.6	0
264	564 Prevalence, Risk Factors, and Global Impact of Musculoskeletal Injuries Among Endoscopists in Portugal. <i>American Journal of Gastroenterology</i> , 2019, 114, S325-S326.	0.2	0
265	P051 Quantifying inflammation and fibrosis through a surgical histopathological score can differentiate ileal Crohn’s disease phenotypes and predict postoperative progressive disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S158-S160.	0.6	0
266	Rehospitalization rates, costs, and risk factors for inflammatory bowel disease: a 16-year nationwide study. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092383.	1.4	0
267	Newborn Congenital Abnormalities and Inflammatory Bowel Disease: Unveiling an Unexplored Relationship. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1033-1034.	0.6	0
268	Prospective study of blood viral load of Epstein-Barr virus, herpes virus type 6 and human parvovirus B19 in Crohn’s disease: Does therapy matter?. <i>Journal of Clinical Virology</i> , 2020, 129, 104515.	1.6	0
269	Severe Hemorrhagic Enteropathy Secondary to <i>Salmonella typhi</i> . <i>GE Portuguese Journal of Gastroenterology</i> , 0, , 1-3.	0.3	0
270	Exploring the Ways of “The Great Imitator” A Case Report of Syphilitic Hepatitis. <i>GE Portuguese Journal of Gastroenterology</i> , 0, , 1-4.	0.3	0

#	ARTICLE	IF	CITATIONS
271	Comment on "The Effect of Hyperbaric Oxygen Therapy on Rectal Ulcers after Argon Plasma Coagulation". GE Portuguese Journal of Gastroenterology, 2022, 29, 1-2.	0.3	0
272	Are we on our way to change our mode of thinking and treating inflammatory bowel disease patients?. Annals of Gastroenterology, 2014, 27, 424-426.	0.4	0
273	Inflammation of the appendix in ulcerative colitis " Does it have a predictive value?. United European Gastroenterology Journal, 2021, 9, 1107-1108.	1.6	0
274	Inflammatory Bowel Disease in migrant populations " a narrative review. Current Drug Targets, 2020, 21, .	1.0	0
275	Letter to the Editor. Journal of Crohn's and Colitis, 2022, , .	0.6	0
276	DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, i129-i130.	0.6	0
277	OUP accepted manuscript. Journal of Crohn's and Colitis, 2022, , .	0.6	0
278	Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures. The Lancet Gastroenterology and Hepatology, 2022, 7, 503.	3.7	0
279	Fibromuscular expansion in Crohn's disease ileal strictures: an open issue. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0